{"id":"atenolol-hctz-trandolapril","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Erectile dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atenolol is a beta-1 selective antagonist that reduces heart rate and cardiac contractility. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that decreases blood volume and sodium reabsorption. Trandolapril is an ACE inhibitor that blocks angiotensin II formation, reducing vasoconstriction and aldosterone secretion. Together, these agents provide synergistic blood pressure reduction.","oneSentence":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: beta-blockade, diuresis, and ACE inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:49.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00133692","phase":"PHASE4","title":"INVEST: INternational VErapamil SR Trandolapril STudy","status":"COMPLETED","sponsor":"University of Florida","startDate":"1997-09","conditions":"Hypertension, Coronary Artery Disease","enrollment":22000},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atenolol/HCTZ/Trandolapril","genericName":"Atenolol/HCTZ/Trandolapril","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: beta-blockade, diuresis, and ACE inhibition. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}